SEC Company Response from CRESCENT BIOPHARMA, INC. (CBIO) (CIK 0001253689) (CBIO) — Nov 5, 2013
CRESCENT BIOPHARMA, INC. (CBIO) (CIK 0001253689)
Date: Nov. 5, 2013 · CIK: 0001253689 · Accession: 0001193125-13-427598
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-191567
Letter
Acceleration Request
401 Professional Drive, Suite 250
Gaithersburg, MD 20879
VIA EDGAR
November 5, 2013
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4720
Washington, D.C. 20549
Attn:
Mr. Matthew Jones
Mr. Dan Greenspan
Mr. Jeffrey Riedler
Re: GlycoMimetics, Inc.
Registration Statement on Form S-1
File No. 333-191567
Acceleration Request
Requested Date:
Thursday, November 7, 2013
Requested Time:
4:00 P.M. Eastern Standard Time
Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on November 7, 2013, at 4:00 p.m., Eastern Standard Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”). The Registrant hereby authorizes each of Brent Siler, Darren DeStefano and Brian Leaf of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP, counsel to the Registrant, at (703) 456-8053.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
GlycoMimetics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request 401 Professional Drive, Suite 250 Gaithersburg, MD 20879 VIA EDGAR November 5, 2013 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attn: Mr. Matthew Jones Mr. Dan Greenspan Mr. Jeffrey Riedler Re: GlycoMimetics, Inc. Registration Statement on Form S-1 File No. 333-191567 Acceleration Request Requested Date: Thursday, November 7, 2013 Requested Time: 4:00 P.M. Eastern Standard Time Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on November 7, 2013, at 4:00 p.m., Eastern Standard Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”). The Registrant hereby authorizes each of Brent Siler, Darren DeStefano and Brian Leaf of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP, counsel to the Registrant, at (703) 456-8053. In connection with this request, the Registrant acknowledges that: • should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, GlycoMimetics, Inc. By: /s/ Rachel K. King Rachel K. King Chief Executive Officer cc: Brent B. Siler, Cooley LLP Darren DeStefano, Cooley LLP Brian F. Leaf, Cooley LLP Divakar Gupta, Latham & Watkins